Tecarfarin, a Novel Vitamin K Reductase Antagonist, Is Not Affected by CYP2C9 and CYP3A4 Inhibition Following Concomitant Administration of Fluconazole in Healthy Participants
Authors:
- Linda M. BavisottoLBLinda M. Bavisotto
- David J. EllisDEDavid J. Ellis
- Peter G. MilnerPMPeter G. Milner
- Daniel L. CombsDCDaniel L. Combs
- Ian IrwinIIIan Irwin
- Daniel M. CanafaxDCDaniel M. Canafax
- 1 April 2011
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 51 (4) , 561-574
Abstract
Comparative pharmacokinetics of vitamin K epoxide reductase antagonists tecarfarin and warfarin were assessed before and after coadministration for 21 days of the CYP450 inhibitor fluconazole in a randomized, open-label, single-center drug interaction study. Twenty healthy adult participants were randomized 1:1 to receive approximately equipotent single oral doses of tecarfarin (50 mg) or warfarin (17.5 mg). Following 7 days of baseline serial blood level collections, each participant received oral fluconazole 400 mg daily for 21 days. A second identical single oral dose of tecarfarin or warfarin was given 14 days after starting fluconazole with serial pharmacokinetic sampling. Key pharmacokinetic parameters C(max), t(max), AUC(0-168), apparent clearance, and t(1/2) demonstrated no tecarfarin-fluconazole interaction but a strong warfarin-fluconazole interaction. The ratio of log-transformed mean AUC(0-168) with versus without fluconazole for tecarfarin was 91.2% (90% confidence interval [CI]: 83.3-99.8) and for racemic warfarin was 213% (90% CI: 202-226). The 90% CI was entirely within the standard 80% to 125% bioequivalence interval for tecarfarin but well outside the bioequivalence interval for warfarin, confirming a clinically significant pharmacokinetic interaction between warfarin and fluconazole. In contrast, tecarfarin pharmacokinetics were apparently unchanged by fluconazole.Keywords
This publication has 18 references indexed in Scilit:
- Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogsBritish Journal of Pharmacology, 2009
- VKORC1 Polymorphisms, Haplotypes and Haplotype Groups on Warfarin Dose Among African–Americans and European–AmericansPharmacogenomics, 2008
- Warfarin With Fluoroquinolones, Sulfonamides, or Azole Antifungals: Interactions and the Risk of Hospitalization for Gastrointestinal BleedingClinical Pharmacology & Therapeutics, 2008
- Pharmacology and Management of the Vitamin K AntagonistsChest, 2008
- Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on WarfarinClinical Pharmacology & Therapeutics, 2007
- Estimation of Warfarin Maintenance Dose Based on VKORC1 (−1639 G>A) and CYP2C9 GenotypesClinical Chemistry, 2007
- Systematic Overview of Warfarin and Its Drug and Food InteractionsArchives of internal medicine (1960), 2005
- Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactionsPharmacoepidemiology and Drug Safety, 2005
- Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 2000
- Systemic Antifungal AgentsDrug Safety, 1998